A method to identify prescription drug targets for health technology reassessment [0.03%]
一种识别卫生技术重新评估的处方药靶点的方法
Mark Hofmeister,Michael R Law,Cheryl A Sadowski et al.
Mark Hofmeister et al.
Introduction: The simultaneous existence of low-value health care and underutilization of high-value care are global problems. Health technology reassessment (HTR) aims to optimize the value for money of technologies alre...
Value-based health care frameworks for the health technology assessments of "omics" technologies: an international survey [0.03%]
基于价值的卫生体系中评估“组学”技术的健康技术评估框架：一项国际调查
Tommaso Osti,Abdelrahman Taha,Eva Reviriego-Rodrigo et al.
Tommaso Osti et al.
Background: Despite omics technologies gaining traction in clinical settings, particularly in oncology, challenges persist in their widespread adoption due to the pre-requisite robust evidence supporting efficacy and cost...
Approaches to Modeling Treatment Sequencing in Practice: A Thematic Review of NICE Appraisals [0.03%]
英国NICE评估中治疗序贯建模方法的主题性综述
Abualbishr Alshreef,Fern Woodhouse,Molly Haycock et al.
Abualbishr Alshreef et al.
DERIVATION OF A SOUTH AFRICAN TARIFF FOR THE EQ-5D-5L USING A PERSONAL UTILITY FUNCTION APPROACH [0.03%]
基于个人效用函数的南非EQ-5D-5L价值体系的建立
Aisha Moolla,Paul Schneider,Karen Hofman et al.
Aisha Moolla et al.
BRIDGING THE GAP BETWEEN EVIDENCE AND PRACTICE: INTRODUCING HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT IN UKRAINE [0.03%]
从证据到实践：在乌克兰建立机构卫生技术评估体系
Olena Filiniuk,Rabia Sucu,Rebecca Kohler et al.
Olena Filiniuk et al.
INCORPORATING ENVIRONMENTAL SUSTAINABILITY INTO HEALTH TECHNOLOGY ASSESSMENT: A QUALITATIVE EXPLORATION [0.03%]
关于健康技术评估中环境可持续性的定性研究
Gillian Parker,Fiona A Miller
Gillian Parker
Coverage With Evidence Development For Medicines with Insufficient Evidence Of Clinical Benefit: Experience From The Netherlands [0.03%]
临床获益证据不足的药品开展边用边证的覆盖经验——来自荷兰的视角
Jan-Willem Versteeg,Noraly Stam,Aukje K Mantel-Teeuwisse et al.
Jan-Willem Versteeg et al.
Cost-Effectiveness Analysis of Blood Cell Separators in Allogeneic Hematopoietic Stem Cell Transplantation: A Perspective from the Chinese Healthcare System [0.03%]
allo-HSCT中血细胞分离机的成本效益分析——来自中国卫生系统的视角
Xiangyan Tang,Hongshu Fang,Mingye Zhao et al.
Xiangyan Tang et al.
NICE's early value assessment: an external assessment group's commentary on the challenges and opportunities of NICE's new life cycle approach to HealthTech [0.03%]
英国NICE的早期价值评估：HealthTech生命周期新方法的挑战和机遇
Alan Lovell,Maxwell S Barnish,Sophie Robinson et al.
Alan Lovell et al.
The National Institute for Health and Care Excellence (NICE) early value assessment (EVA) was launched in 2022 as a process to assess new technologies that have the potential to meet an unmet need or demand. The recommendations that result ...
MAPPING CURRENT DECISION-MAKING PATHWAYS AND REIMBURSEMENT PROCESSES FOR HIGH-RISK MEDICAL DEVICES IN EU/EEA MEMBER STATES AND THE UK: A SCOPING REVIEW [0.03%]
欧盟/欧洲经济区成员国和英国高风险医疗器械现行决策审批途径和报销流程的综述性研究
Rasha A Alshaikh,Kieran A Walsh,Fatma El-Komy et al.
Rasha A Alshaikh et al.